Market Signal Briefing

For the quarter ended December 2025, Arrow Electronics (ARW - Free Report) reported revenue of $8.75 billion, up 20.1% over the same period last year. EPS came in at $4.39, compared to $2.97 in the year-ago quarter.

The reported revenue represents a surprise of +7.97% over the Zacks Consensus Estimate of $8.1 billion. With the consensus EPS estimate being $3.55, the EPS surprise was +23.66%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Arrow Electronics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Geographic Revenue- Americas Components sales, as reported: $1.96 billion compared to the $1.67 billion average estimate based on two analysts. The reported number represents a change of +22.2% year over year.Geographic Revenue- Americas ECS sales as reported: $1.25 billion versus the two-analyst average estimate of $1.32 billion. The reported number represents a year-over-year change of +7.2%.Geographic Revenue- Asia components sales, as reported: $2.46 billion compared to the $2.22 billion average estimate based on two analysts. The reported number represents a change of +26.4% year over year.Geographic Revenue- EMEA ECS sales as reported: $1.62 billion versus the two-analyst average estimate of $1.48 billion. The reported number represents a year-over-year change of +23.8%.Geographic Revenue- EMEA components sales, as reported: $1.46 billion compared to the $1.4 billion average estimate based on two analysts. The reported number represents a change of +15.7% year over year.Net Sales- Global ECS: $2.86 billion compared to the $2.8 billion average estimate based on three analysts. The reported number represents a change of +16% year over year.Net Sales- Global components: $5.88 billion versus the three-analyst average estimate of $5.3 billion. The reported number represents a year-over-year change of +22.2%.View all Key Company Metrics for Arrow Electronics here>>>

Shares of Arrow Electronics have returned +23.7% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Operator

Hello, everyone. Thank you for joining us, and welcome to the Good Times Restaurants, Inc. Q1 2026 Earnings Call. [Operator Instructions]

I will now hand the call over to Keri August, Chief Accounting Officer. Please go ahead.

Keri August
Senior VP of Finance & Accounting and Corporate Secretary

Thank you, Elodie. Good afternoon, ladies and gentlemen, and welcome to the Good Times Restaurants, Inc. Fiscal 2026 First Quarter Earnings Call. I am Keri August, the company's Chief Accounting Officer. By now, everyone should have access to the company's earnings release, which is available in the Investors section of the company's website.

As a reminder, a part of today's discussion will include forward-looking statements within the meaning of federal securities laws. These forward-looking statements are not guarantees of future performance, and therefore, you should not put undue reliance on them. These statements involve known and unknown risks, which may cause the company's actual results to differ materially from results expressed or implied by the forward-looking statements.

Such risks and uncertainties include, among other things, the market price of the company's stock prevailing from time to time, the nature of other investment opportunities presented to the company, the disruption to our business from pandemics and other public health emergencies, the impact of staffing constraints at our restaurants, the impact of supply chain constraints and inflation, the uncertain nature of current restaurant development plans and the ability to implement those plans and integrate new restaurants, delays in developing and opening new restaurants because of weather, local permitting or other reasons, increased competition, cost increases or ingredient shortages, general economic and operating

Affirm’s fiscal second quarter illustrated how buy now, pay later is becoming embedded in routine commerce, where paying over time was once reserved for occasional large purchases.

The company said Thursday (Feb. 5) that gross merchandise volume (GMV) increased 36% year over year to $13.8 billion, while revenue climbed 30% to $1.1 billion. Network growth continued to broaden, with active consumers as of the end of last year rising 23% to 25.8 million, transactions per active consumer increasing 20% to 6.4, and active merchants expanding 42% to roughly 478,000, reflecting deeper engagement on both sides of the platform.

Growth came from a mix of point-of-sale integrations, wallet partnerships and Affirm’s direct-to-consumer business, led by the Affirm Card. Direct-to-consumer GMV rose 52% to $4.3 billion, driven primarily by Card volume, which surged 159% to $2.2 billion. Active cardholders more than doubled to 3.7 million, pushing card attach rates to about 14%.

Zero Interest Becomes Central to Checkout Zero-interest financing played an increasingly central role in those results. GMV tied to 0% APR products, including Pay-in-X, grew 60% and continued to outpace overall platform growth. More than 60% of new Affirm customers chose a 0% option for their first transaction, the company said, and nearly 39% of all purchases during the quarter carried no interest. Roughly 60,000 merchants funded 0% APR offers during the period, nearly quadruple the prior year, underscoring how sellers are using these programs as a demand-generation tool rather than a limited promotion.

On the earnings call, CEO Max Levchin said Affirm’s approach rests on clarity at checkout, even as competitors experiment with more complicated offers.

“When Affirm says no interest, we actually mean no interest and there’s no asterisk,” Levchin told analysts. He added that Affirm’s pitch remains deliberately simple: “You are [paying] no interest. … It’s so easy to understand.”

Advertisement: Scroll to Continue

That simplicity, Levchin said, has limited the impact of aggressive cashback campaigns elsewhere in the market. “We saw no effects,” he said. “All those promotional go-to-market motions just don’t seem to make a dent in what we sell.”

Affirm Card Extends BNPL Into Daily Spend The Affirm Card continued to shift BNPL toward everyday usage. Card-based 0% APR GMV increased 190% year over year and now represents close to 20% of total Card volume, reflecting a steady migration from one-time installment purchases to repeat activity across categories.

Levchin described the Card as moving beyond its early adopter phase. “It’s no longer a cool novelty product for our die-hard users,” he said. “It’s helping us create more die-hard users.”

He also addressed the common assumption that customers who begin with promotional financing resist interest-bearing products later on. “There’s an industry myth that you self-select into a zero-APR deal and then react violently when it changes upward,” Levchin said. “That is not the case with the Affirm consumer.”

Consumer Health and Credit Remain Steady Affirm reported stable credit performance alongside rising volumes. Thirty-plus-day delinquencies on monthly installment loans stood at 2.7%, up year over year but down sequentially, while recent cohorts continue to track toward roughly 3.5% net charge-offs. Pay-in-4 losses remained below 1% of GMV, and allowance for credit losses held at 5.4% of loans held for investment, consistent with last year.

Levchin characterized the customer base as resilient despite persistent macroeconomic uncertainty.

“The consumer we see today is quite healthy,” he said. “They’re able and willing to pay us back. They’re borrowing money. We feel pretty good about both the demand and the ability and willingness to repay.”  He added that quarter-to-date trends have not materially diverged from conditions exiting December.

Affirm’s internally developed AdaptAI and BoostAI systems increasingly shape financing offers and merchant performance. BoostAI, which runs automated A/B tests and deploys merchant-funded incentives, is now live across dozens of enterprise merchants and hundreds of small businesses.

Levchin described BoostAI as allowing merchants to allocate incremental dollars while Affirm determines how best to deploy them. “It allows a merchant to say, ‘I have $100,000 more dollars I’d like to put into Affirm-specific promotions, 0% or just reduced APRs, and you guys go A/B test who is most likely to convert.’”

New Verticals and Regulatory Positioning During the quarter, Affirm expanded partnerships with major retailers, embedded pay-over-time into QuickBooks Payments for service providers, and began limited testing in rent-related use cases. Levchin stressed that the rental pilot is narrowly focused on timing mismatches, such as bridging paydays and due dates, rather than turning rent into long-term installment debt. “It’s very small,” he said. “Put nothing in your models for now,” he told analysts.

Levchin also expanded on the end of January announcement that it has applied for an industrial bank charter. Levchin framed the move primarily as a bid for regulatory clarity. He told analysts that owning a regulated subsidiary would provide clearer footing for partners and the company. He cautioned that approval timelines stretch over years and outcomes remain uncertain, characterizing the effort as a long-term investment rather than an immediate growth driver.

Affirm projected GMV in the current fiscal year of $48.3 billion to $48.85 billion (a deceleration from recent growth rates) and revenue between roughly $4.09 billion and $4.15 billion, with operating margins expected to improve in the second half of the year. Shares slipped 6% in after-hours trading on Thursday.

The quarter ultimately reflected a company pressing deeper into everyday commerce expanding distribution via the Affirm Card and partners, and increasingly automated decisioning. For Levchin, the strategy centers on keeping financing straightforward at checkout while the infrastructure behind it all becomes more sophisticated.

New York, New York--(Newsfile Corp. - February 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ardent Health, Inc. (NYSE: ARDT) between July 18, 2024 and November 12, 2025, both dates inclusive (the "Class Period"), of the important March 9, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Ardent Health securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Ardent Health class action, go to https://rosenlegal.com/submit-form/?case_id=50392 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 9, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made misrepresentations regarding Ardent Health's accounts receivable. Defendants publicly reported Ardent Health's accounts receivable on a quarterly basis. They further stated that Ardent Health employed an active monitoring process to determine the collectability of its accounts receivable, and that this process included "detailed reviews of historical collections" as a "primary source of information." Further, defendants represented that Ardent Health considered "trends in federal and state governmental healthcare coverage" and that its "management determines [when an] account is uncollectible, at which time the account is written off." When defendants began to reveal increased claim denials by third-party payors, they downplayed the issue, stating that the increased payor denials were "turning [] more into a slow pay versus not getting paid," and did not write-off the uncollectible accounts. In addition, defendants represented that Ardent Health maintained professional malpractice liability insurance in amounts "sufficient to cover claims arising out of [its] operations[.]" In truth, Ardent Health did not primarily rely on "detailed reviews of historical collections" in determining collectability of accounts receivable nor did "management determine[] [when an] account is uncollectible." Instead, Ardent Health's accounts receivable framework "utilized a 180-day cliff at which time an account became fully reserved." This allowed Ardent Health to report higher amounts of accounts receivable during the Class Period, and delay recognizing losses on uncollectable accounts. And Ardent Health did not even maintain professional malpractice liability insurance in amounts "sufficient to cover claims arising out of [its] operations[.]" In truth, Ardent Health's professional liability reserves were insufficient to cover "significant social inflationary pressure in medical malpractice cases the past several years," which had been an "increasing dynamic year-over-year" in Ardent Health's New Mexico market. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ardent Health class action, go to https://rosenlegal.com/submit-form/?case_id=50392 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282965

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Weight management concerns should be evaluated by a qualified healthcare professional. Hims GLP-1 Weight Loss is a prescription-only medication program available exclusively through licensed physician consultation. This content does not diagnose, treat, cure, or prevent any disease. Prescription approval is not guaranteed. If you purchase through links in this article, a commission may be earned at no additional cost to you.

Purpose and Scope

This release is an informational overview of publicly available disclosures for Hims GLP-1 Weight Loss and broader consumer research behavior within the prescription weight loss treatment access through telehealth platforms category. Nothing in this content should be interpreted as medical advice, a product endorsement, or a performance claim.

As consumer interest in prescription weight loss treatment access through telehealth platforms continues to grow heading into 2026, updated service disclosures for Hims GLP-1 Weight Loss—a prescription-only offering—have recently become publicly available. More people are researching telehealth-based weight loss treatment options online, and detailed information about the Hims platform's physician-supervised weight management protocols is now accessible for anyone exploring their options.

This article provides informational context about the telehealth weight loss category and summarizes what Hims has disclosed about its telehealth service. Readers seeking primary-source detail can view the current Hims GLP-1 Weight Loss offer (official Hims page) to review the company's published service disclosures directly. Nothing in this content should be interpreted as medical advice, an endorsement, or a treatment recommendation.

What Changed on February 5, 2026

On February 5, 2026, multiple outlets reported that Hims & Hers said it is launching a compounded semaglutide pill option and that Novo Nordisk responded by criticizing the move and signaling potential legal action. This release summarizes publicly available company disclosures and reported developments in the prescription weight loss telehealth category for informational purposes only.

The reported developments follow increased public discussion around compounded GLP-1 medications and telehealth access, making this a particularly active moment for consumers researching their options. For anyone following developments in the GLP-1 category and trying to sort out what is actually available, what it costs, and what the differences are between branded and compounded medications, this article is designed to present the publicly available facts so that consumers can make their own informed decisions.

Some third-party reporting described Novo Nordisk leadership as strongly criticizing the idea of compounded pill versions and questioning their value, while reiterating that only the FDA-approved product has been through the agency's approval process. According to the company's own disclosures, Hims states that its compounded products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Both perspectives are part of the public record, and consumers evaluating this category should consider all available information.

Why Consumer Interest in Telehealth-Based Weight Loss Treatment Is Rising

Anyone who has spent time researching prescription weight loss treatment over the past couple of years has likely noticed how much the landscape has changed. A class of medications known as GLP-1 receptor agonists—originally developed for type 2 diabetes management—has become a major focal point of consumer interest after certain formulations received FDA approval for weight management. Public health guidance commonly encourages individuals to discuss weight management strategies, including prescription options, with qualified healthcare professionals.

Within this broader trend, telehealth platforms offering prescription weight loss medications have become a category that more consumers report researching. For many people, the appeal comes down to accessibility—the ability to consult with a licensed provider, receive a clinical evaluation, and potentially obtain a prescription without visiting a physical clinic. The research process often involves understanding what platforms are available, what medications might be prescribed, what the costs look like, and what factors might be worth considering when comparing services.

One thing worth understanding upfront: prescription medications in this category require clinical evaluation by a licensed healthcare provider. Signing up for a telehealth platform does not guarantee that a prescription will be issued. That decision rests entirely with the evaluating provider based on the individual's medical history, health profile, and clinical appropriateness.

What Prescription Weight Loss Treatment Access Through Telehealth Typically Refers To

When people refer to "prescription weight loss treatment access through telehealth platforms," they are generally describing services that connect consumers with licensed healthcare providers through online consultations. The provider evaluates whether prescription weight loss medication may be clinically appropriate for the individual's situation, and if so, the platform typically handles the prescribing, pharmacy fulfillment, and ongoing care through a single digital experience.

Within this category, the types of medications that licensed providers may prescribe generally fall into several groups. There are FDA-approved GLP-1 receptor agonist medications specifically indicated for weight management, FDA-approved medications that providers sometimes prescribe off-label for weight management at their clinical discretion, compounded medications prepared by licensed pharmacies based on individual prescriptions, and oral medication combinations. Understanding the regulatory distinctions between these medication types is an important part of making an informed decision.

FDA-Approved vs. Compounded: What the Labels Mean

This is one of the most important distinctions for anyone researching this category, and it is worth taking a moment to get it right.

FDA-approved branded medications—like Wegovy (semaglutide) and Zepbound (tirzepatide)—have gone through the FDA's full approval process. That process includes clinical trials evaluating safety, efficacy, and manufacturing quality. These brand-name medications are referenced as examples within the broader GLP-1 category; any prescribing decisions are made independently by licensed providers based on individual clinical appropriateness.

Compounded medications are different. They are prepared by licensed pharmacies based on individual prescriptions, but they have not gone through the FDA's approval process as finished drug products. The FDA has emphasized that compounded drugs are not FDA-approved and are not evaluated by the agency for safety, effectiveness, or quality before dispensing. That does not mean compounded medications are illegal—compounding is a legitimate practice in pharmacy—but the regulatory status is fundamentally different from FDA-approved products, and that distinction matters when evaluating available options.

Regulators have previously cautioned that marketing for compounded GLP-1 products should not imply equivalence to FDA-approved medications, and consumers evaluating this category may wish to review FDA communications alongside company disclosures.

Off-label prescribing is another term consumers may encounter. This is the practice of prescribing an FDA-approved medication for a use other than its primary approved indication. It is legal and common in medicine—but it means the FDA has not specifically evaluated the medication for that particular use.

How Telehealth Weight Loss Platforms Generally Operate

Telehealth platforms in this category commonly describe workflows that may include an online health assessment covering medical history, current medications, and relevant health information. A licensed healthcare provider then reviews the submitted information and makes an independent clinical determination about whether prescription medication is appropriate for the individual's situation.

If the provider determines medication is clinically warranted, a prescription is issued and the medication ships directly to the consumer. Ongoing care—including dosage adjustments and follow-up consultations—is generally available through the platform. Clinical guidance generally emphasizes that weight management is a long-term process, and medication decisions should be made in consultation with a provider who can monitor progress and adjust treatment as needed.

One practical detail worth knowing: state regulations affect availability for every platform in this category. Not all services are available in every state, and prescribing requirements—including whether a video consultation is required—vary by jurisdiction. Consumers should verify state-specific availability before starting any telehealth weight loss program.

What Hims Discloses About Its GLP-1 Weight Loss Service

According to publicly available company disclosures, Hims GLP-1 Weight Loss is a telehealth-based weight management program operated by Hims & Hers Health, Inc., a publicly traded company (NYSE: HIMS) headquartered in San Francisco, California, according to company materials. The platform connects consumers with licensed healthcare providers who evaluate whether prescription weight loss medication may be clinically appropriate on an individual basis.

The company's published materials indicate that the platform offers access to multiple categories of weight loss treatment, including FDA-approved branded GLP-1 medications, compounded GLP-1 medications, and oral medication kits. According to the company, FDA-approved medications available through the platform include Wegovy (semaglutide) and Zepbound (tirzepatide), both FDA-approved for weight management, along with medications that may be prescribed off-label at the provider's clinical discretion.

The company also discloses that compounded semaglutide—including both injectable and oral pill formulations—is available through the platform. According to Hims, compounded medications are prepared by licensed pharmacies based on individual prescriptions. The company's own disclosures state that compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA.

Additionally, according to company materials, oral medication kits may include combinations of metformin, bupropion, topiramate, naltrexone, and vitamin B12, prescribed at the evaluating provider's discretion. These oral kits are distinct from GLP-1 medications and work through different mechanisms.

According to the company, all treatment plans require evaluation and prescribing by a licensed healthcare provider. The platform states that prescription approval is not guaranteed and that the evaluating provider makes independent clinical decisions based on the individual's health profile. The company also discloses that GLP-1 treatment options are not currently available in all 50 states.

Reported Pricing

Reported pricing for the newly announced compounded semaglutide pill option has been described as starting at $49 for an introductory month for certain customers, with additional pricing and eligibility varying by plan and clinical determination. Consumers should verify current pricing, availability, and state-specific access directly through the company's published disclosures, as details may change over time.

Telehealth Access: What Varies by State

Consumers considering a telehealth-based weight loss program should first verify whether the service is available in their state. Telehealth prescribing regulations vary significantly by state, and platforms like Hims may not be able to offer certain medications or treatment plans in every jurisdiction. Some states require a video consultation before a prescription can be issued, while others allow treatment to be determined based on a written health assessment. According to company disclosures, Hims states that GLP-1 treatment options are not currently available in all 50 states and that availability is expanding over time.

Provider Evaluation: Why Prescriptions Are Not Guaranteed

This is a common point of confusion, so it is worth stating clearly. Completing an intake form on a telehealth platform does not mean a prescription will automatically be issued. A licensed healthcare provider reviews the submitted health information and makes an independent clinical decision about whether medication is appropriate for that individual's specific situation. Some people qualify, and some do not—and that determination is based on the individual's health profile, not on whether the form was completed.

According to Hims, the platform's providers are licensed and trained in weight management, and all prescribing decisions are made independently based on clinical appropriateness. If a provider determines that medication is not appropriate for a particular individual, that reflects the provider's independent clinical judgment.

Safety Monitoring Questions Consumers Often Ask Providers

Consumers researching GLP-1 weight loss medications often have questions about what ongoing care and monitoring look like once treatment begins. Based on publicly available guidance, common questions include what side effects to expect during the initial titration period, how dosage adjustments are handled over time, what warning signs should prompt immediate contact with a provider, and how long treatment is typically continued.

According to company disclosures, Hims states that ongoing provider access—including messaging for follow-up questions and dosage adjustments—is available through the platform. Clinical guidance generally emphasizes that any prescription weight loss treatment should include regular monitoring by a qualified healthcare professional.

Refund Policies and Customer Support Disclosures

According to the company's published policies, Hims describes refund and cancellation policies and provides customer service contact methods on its website. Readers should review the full terms directly on the official page, as policy details and eligibility requirements may vary based on the specific treatment plan purchased.

When to Consult a Healthcare Professional

While telehealth platforms have expanded access to weight management consultations, certain individuals should discuss any weight loss treatment plan with a qualified healthcare professional who has access to their full medical history. This commonly includes people with cardiovascular conditions, individuals managing type 2 diabetes, those with a history of thyroid conditions including medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, individuals with a history of pancreatitis, those taking medications that may interact with GLP-1 receptor agonists, individuals with kidney or liver conditions, and those who are pregnant or nursing.

Many people choose to consult qualified healthcare professionals for personalized guidance on whether any prescription weight loss treatment fits their individual health circumstances. Telehealth consultations are one avenue for that guidance, but consumers with complex medical histories may benefit from in-person evaluation as well.

Informational Resources and Primary-Source Access

Consumers researching Hims GLP-1 Weight Loss who want to go deeper than what this article covers can access the company's complete service disclosures, medication information, pricing details, and eligibility requirements directly through the official Hims platform. Readers interested in primary-source information can visit the official Hims GLP-1 Weight Loss page to access the company's published disclosures directly.

Phone: 1-800-368-0038Support: https://support.hims.com/hc/en-us This article is for informational purposes only and does not constitute medical advice, a product endorsement, or a treatment recommendation. All prescription medication decisions should be made in consultation with a qualified, licensed healthcare professional.

For the quarter ended December 2025, Ventas (VTR - Free Report) reported revenue of $1.57 billion, up 21.7% over the same period last year. EPS came in at $0.89, compared to $0.13 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $1.5 billion, representing a surprise of +4.68%. The company delivered an EPS surprise of +0.38%, with the consensus EPS estimate being $0.89.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Ventas performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Interest and other income: $7.88 million versus the two-analyst average estimate of $2.25 million. The reported number represents a year-over-year change of -5.2%.Revenues- Rental income- Outpatient medical & research portfolio: $226.76 million versus $229.22 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change.Revenues- Resident fees and services: $1.19 billion versus $1.11 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +32.3% change.Net Earnings Per Share (Diluted): $0.15 compared to the $0.12 average estimate based on two analysts.View all Key Company Metrics for Ventas here>>>

Shares of Ventas have returned +2.7% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

For the quarter ended December 2025, Cousins Properties (CUZ - Free Report) reported revenue of $253.34 million, up 15% over the same period last year. EPS came in at $0.71, compared to $0.09 in the year-ago quarter.

The reported revenue represents a surprise of +0.49% over the Zacks Consensus Estimate of $252.1 million. With the consensus EPS estimate being $0.71, the company has not delivered EPS surprise.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Cousins Properties performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Other: $1.16 million versus the two-analyst average estimate of $0.8 million. The reported number represents a year-over-year change of -74.9%.Revenues- Rental property: $253.34 million versus the two-analyst average estimate of $244.68 million. The reported number represents a year-over-year change of +15%.Revenues- Fee income: $0.53 million versus $0.53 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.8% change.View all Key Company Metrics for Cousins Properties here>>>

Shares of Cousins Properties have returned +0.6% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

For the quarter ended December 2025, Boyd Gaming (BYD - Free Report) reported revenue of $1.06 billion, up 2% over the same period last year. EPS came in at $2.21, compared to $1.96 in the year-ago quarter.

The reported revenue represents a surprise of +5.73% over the Zacks Consensus Estimate of $1 billion. With the consensus EPS estimate being $1.88, the EPS surprise was +17.3%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Boyd performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues by Segment- Managed & Other: $38.69 million versus $37.49 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +7.3% change.Revenues by Segment- Downtown Las Vegas: $62.97 million compared to the $65.21 million average estimate based on five analysts. The reported number represents a change of -3.9% year over year.Revenues by Segment- Midwest and South: $533.08 million versus $521.91 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +2.8% change.Revenues by Segment- Las Vegas Locals: $227.23 million versus the five-analyst average estimate of $229.55 million. The reported number represents a year-over-year change of -2.1%.Adjusted EBITDAR- Online: $8.17 million versus $5.46 million estimated by five analysts on average.Adjusted EBITDAR- Managed & Other: $28.59 million versus the five-analyst average estimate of $26.1 million.Adjusted EBITDAR- Corporate expense: $-24.7 million versus $-23.86 million estimated by five analysts on average.Adjusted EBITDAR- Downtown Las Vegas: $24.01 million versus the five-analyst average estimate of $26.15 million.Adjusted EBITDAR- Midwest and South: $191.43 million compared to the $190.75 million average estimate based on five analysts.Adjusted EBITDAR- Las Vegas Locals: $109.12 million versus the five-analyst average estimate of $107.59 million.View all Key Company Metrics for Boyd here>>>

Shares of Boyd have returned -1.5% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Post Holdings (POST - Free Report) reported $2.17 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 10.1%. EPS of $2.13 for the same period compares to $1.73 a year ago.

The reported revenue represents a surprise of +0.46% over the Zacks Consensus Estimate of $2.16 billion. With the consensus EPS estimate being $1.66, the EPS surprise was +28.57%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Post Holdings performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- Post Consumer Brands: $1.1 billion versus $1.11 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.5% change.Net Sales- Foodservice: $669.1 million versus the three-analyst average estimate of $649.93 million. The reported number represents a year-over-year change of +8.5%.Net Sales- Refrigerated Retail: $266.6 million compared to the $275.23 million average estimate based on three analysts. The reported number represents a change of 0% year over year.Net Sales- Weetabix: $137.9 million compared to the $131.48 million average estimate based on three analysts. The reported number represents a change of +8.1% year over year.Adjusted EBITDA- Post Consumer Brands: $203.3 million compared to the $206.39 million average estimate based on three analysts.Adjusted EBITDA- Weetabix: $33.1 million versus $30.47 million estimated by three analysts on average.Adjusted EBITDA- Foodservice: $152.4 million versus the three-analyst average estimate of $120.76 million.Adjusted EBITDA- Corporate/ Other: $-20.7 million versus the three-analyst average estimate of $-21 million.Adjusted EBITDA- Refrigerated Retail: $50.1 million versus the three-analyst average estimate of $48.79 million.View all Key Company Metrics for Post Holdings here>>>

Shares of Post Holdings have returned +8.3% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Klarna Group plc (NYSE: KLAR) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Klarna’s September 2025 initial public offering (the “IPO”), of the important February 20, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Klarna securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Klarna class action, go to https://rosenlegal.com/submit-form/?case_id=48971 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Registration Statement contained false and/or misleading statements and/or failed to disclose that: (1) Defendants materially understated the risk that Klarna’s loss reserves would materially go up within a few months of the IPO, which they either knew of or should have known of given the risk profile of many individuals agreeing to Klarna’s buy now, pay later (“BNPL”) loans; and (2); as a result, defendants’ public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Klarna class action, go to https://rosenlegal.com/submit-form/?case_id=48971 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

BEIJING, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Yimutian Group (“Yimutian” or the “Company”), a leading digital agriculture platform in China, announced that it has entered into a preliminary acquisition agreement with Hunan Jiufeng Agriculture Co., Ltd. (“Jiufeng Agriculture”), a well-established producer of premium camellia oil products.

The proposed transaction represents a strategic shift for Yimutian as it builds an integrated agricultural ecosystem spanning production, circulation, and consumer markets. By integrating Jiufeng Agriculture’s origin-based resources with its existing digital infrastructure, the Company seeks to enhance product standardization, traceability, and commercialization efficiency. This move allows Yimutian to extend its capabilities beyond B2B services and further into consumer-facing segments.

Founded in 2012, Jiufeng Agriculture operates a vertically integrated camellia oil business covering oil-tea cultivation, raw material processing, oil pressing, refining, and branded product sales. The company has invested approximately RMB 110 million in high-standard oil-tea plantations totaling nearly 30,000 mu (approximately 2,000 hectares) and participated in an agricultural consortium managing more than 150,000 mu of oil-tea farmland.

Jiufeng Agriculture is located in Yueyang County, Hunan Province, one of China’s nationally designated key camellia oil production regions, known for its favorable climate conditions and long-standing cultivation heritage. The region provides stable access to high-quality raw materials, supporting product consistency and long-term supply reliability.

Yimutian plans to deploy its digital and AI-enabled technologies across multiple stages of the camellia oil value chain. Data-driven tools will support planting optimization at the production level, while intelligent manufacturing systems will enhance efficiency and quality control during processing. On the consumer side, the Company intends to leverage digital distribution channels and AI-powered marketing to broaden market reach domestically and internationally.

“Our long-term vision is to create a technology-driven agricultural ecosystem that connects production with consumption,” said Jinhong Deng, Chairman and Chief Executive Officer of Yimutian Group. “By applying AI and data throughout the value chain, we aim to improve production efficiency, strengthen quality assurance, and unlock greater commercial value for agricultural products. Ultimately, our goal is to make every acre of farmland more valuable.”

The proposed transaction is subject to further due diligence, negotiation of definitive agreements, and customary closing conditions. There can be no assurance that the transaction will be completed on the terms currently contemplated, or at all.

About Yimutian Inc:

Yimutian Inc, is a leading agricultural B2B platform in mainland China. Over a decade, the company has been dedicated to digitalizing China’s agricultural product supply chain infrastructure to streamline the agricultural product transaction process, and making it efficient, transparent, secure, and convenient.

For more information, please visit https://ir.ymt.com/ 

About Jiufeng Agriculture:

Hunan Jiufeng Agricultural Development Co., Ltd., founded in 2012, is an edible oil processing and sales enterprise integrating camellia oil planting, camellia fruit processing, as well as the pressing and refining of camellia seed oil and rapeseed oil. With an investment of 110 million yuan, the company has planted nearly 30,000 mu of high-standard camellia oleifera forests, and has joined hands with nearly 150,000 mu of camellia oleifera forests under 13 specialized camellia oil cooperatives to form a Hunan agricultural industrial consortium.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, these forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

For investor inquiries, please contact:

Email: [email protected] 
Phone: +86 1057086561

For media inquiries, please contact:

Email: [email protected]

Image: Bigstock

Read MoreHide Full Article

Key Takeaways Market Indexes Remained "Risk Off" on Myriad ConcernsAmazon Beats Earnings, but Spooked Investors on Huge CapExOther Key Reports This Afternoon Include Roblox and Affirm Thursday, February 5th, 2026

Market indexes scuba-dived today: went below the surface and stayed there, across the board. Bitcoin, metals and apparently equities are all being painted with the same quivering-hand brush. The Dow shed -592 points, -1.20%, the S&P 500 was -84, -1.23%, the Nasdaq -363, -1.59% and the small-cap Russell 2000 lost -46 points, -1.79%.

Earnings Reports After Today’s Close
Amazon (AMZN - Free Report) posted mixed Q4 results after today’s closing bell, with earnings of $1.95 per share coming in light of the Zacks consensus by 3 cents (though nicely above the $1.86 per share reported in the year-ago quarter). Revenues outperformed slightly for the quarter: $213.4 billion versus the $211.5 billion anticipated. Amazon Web Services (AWS) outpaced expectations, $35.6 billion versus $34.9 billion.

None of this explains why shares are trading down -8% in after hours, but this does: $200 billion in projected capex spending, presumably to keep up in the AI infrastructure race with companies like Alphabet (GOOGL - Free Report) and Meta (META - Free Report) . But we saw Microsoft (MSFT - Free Report) fall off on their aggressive buy in this space, as well; as long as the AI trade remains suspect, massive expenditures into it aren’t going to be met with much but disdain.

This is before mentioning the 16K layoffs at the corporation this week, bringing Amazon’s grand total to 30K employees laid off since late last year. I guess $200 billion in spending doesn’t come cheaply, especially with lower-than-expected operating income in the current quarter. Amazon also saw its string on 12 straight quarterly earnings beats come to an end today.

Elsewhere, Roblox (RBLX - Free Report) shares are up +20% on its Q4 earnings release this afternoon, with a better-than-expected loss per share of -$0.45, four cents better than the Zacks consensus. Daily Active Users (DAUs) grew +69% year over year to 144 million, with Hours Engages way up, +88%, to 35 billion.

Buy-now, pay-later platform Affirm (AFRM - Free Report) stormed past estimates in its fiscal Q2 report after the close — earnings of 37 cents grew +61% year over year, and well ahead of the 28 cents per share expected. Revenues of $1.12 billion outpaced the $1.06 billion expected, with Gross Merchandise Volume (GMV) up +36%, but none of this was enough to send shares down another -4% in late trading. Worries over deterioration in consumer credit continue.

Questions or comments about this article and/or author? Click here>>

Published in earnings

People walk past an anti-US mural on a street in Tehran, Iran, February 5, 2026. Majid Asgaripour/WANA (West Asia News Agency) via REUTERS Purchase Licensing Rights, opens new tab

SINGAPORE, Feb 6 (Reuters) - U.S. crude futures extended their decline on Friday, on track for their first weekly drop in weeks, as concerns of supply disruption in the Middle East eased with investors focusing on the outcome of U.S.-Iran nuclear talks in Oman later in the day.

U.S. West Texas Intermediate crude was at $62.47 a barrel by 0013 GMT, down 82 cents or 1.3%, after closing 2.84% lower on Thursday.

The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.

The U.S. and Iran have agreed to hold talks in Oman on Friday amid heightened tensions as the U.S. builds up forces in the Middle East and regional players seek to avoid a military confrontation that many fear could escalate into a wider war.

About a fifth of the world's total oil consumption passes through the Strait of Hormuz between Oman and Iran. Other OPEC members, Saudi Arabia, the United Arab Emirates, Kuwait and Iraq, export most of their crude via the strait, as does Iran.

"Escalating geopolitical tensions between the U.S. and Iran have contributed to higher oil prices," Capital Economics analysts said in a note.

"But we think that geopolitical fears will give way to weak fundamentals," they said, pointing to a recovery in Kazakhstan's oil output which will help push oil prices lower towards $50 per barrel by end-2026.

Reporting by Florence Tan; Editing by Chris Reese

Our Standards: The Thomson Reuters Trust Principles., opens new tab

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on TrumpRx.

TrumpRx is a website that lists discounted cash prices from pharmaceutical manufacturers. TrumpRx does not sell or dispense drugs. Instead, TrumpRx facilitates consumer access to the selected discount, and then the underlying partner platform executes the pricing.

At launch, GoodRx is the integrated pricing source for Pfizer, including over 30 of Pfizer’s essential brand medications, along with other leading pharmaceutical manufacturers. Additional manufacturer integrations are expected to follow.

“Transparent direct-to-consumer prescription pricing helps to ensure millions of Americans have access to the healthcare they deserve,” said Wendy Barnes, President and CEO of GoodRx. “GoodRx gives manufacturers a proven way to launch discounted cash pricing at scale and extend it directly into TrumpRx. We’re starting with essential brand medications from Pfizer and other manufacturers, with additional programs coming soon. Together, we’re turning the promise of prescription drug affordability into a reality for millions of Americans.”

Significant Savings for Over 30 Pfizer Medications Available via GoodRx

Coinciding with the TrumpRx launch, Pfizer is introducing significant discounts for more than 30 of its essential brand medications spanning women’s health, migraine, arthritis, rare disease, and more. Eligible patients may find the prices on TrumpRx and then seamlessly access the GoodRx-enabled savings that range as high as 85% and on average 50%, for the large majority of Pfizer’s primary care treatments and select specialty brands.

To help consumers find these new low prices through a simple and trusted entry point, GoodRx has launched its Pfizer-branded digital storefront.

How GoodRx Helps Pharma Operationalize the TrumpRx Approach

This announcement reinforces GoodRx’s role as a proven integration layer for emerging pricing models. By offering manufacturers a turnkey, scalable way to publish discounted cash prices and extend them to TrumpRx, GoodRx reduces complexity by unifying pricing, pharmacy enablement, and a trusted consumer experience into a single solution. As a result, manufacturers can rapidly operationalize most favored nation (MFN) and other policy-aligned pricing programs at national scale, helping reach more patients, accelerating adoption, and supporting consistently accessible savings at the pharmacy counter.

About GoodRx

GoodRx is the leading platform for prescription savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.

​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of GoodRx’s partnership with Pfizer or TrumpRx; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Reddit, Inc. (RDDT) Q4 2025 Earnings Call February 5, 2026 4:30 PM EST

Company Participants

Jesse Rose - Head of Investor Relations
Steven Huffman - Co-Founder, CEO, President & Director
Jennifer Wong - Chief Operating Officer
Andrew Vollero - Chief Financial Officer

Conference Call Participants

Ronald Josey - Citigroup Inc., Research Division
Benjamin Black - Deutsche Bank AG, Research Division
Thomas Champion - Piper Sandler & Co., Research Division
Justin Post - BofA Securities, Research Division
John Colantuoni - Jefferies LLC, Research Division
Richard Greenfield - LightShed Partners, LLC
Vasily Karasyov - Cannonball Research, LLC
Jason Helfstein - Oppenheimer & Co. Inc., Research Division
Josh Beck - Raymond James & Associates, Inc., Research Division
Naved Khan - B. Riley Securities, Inc., Research Division
Andrew Boone - Citizens JMP Securities, LLC, Research Division
Colin Sebastian - Robert W. Baird & Co. Incorporated, Research Division

Presentation

Operator

Good afternoon. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome everyone to Reddit's Fourth Quarter 2025 Earnings Call.

[Operator Instructions]. I would now like to turn the conference over to Jesse Rose, Head of Investor Relations. Jesse, you may begin your conference.

Jesse Rose
Head of Investor Relations

Thanks, Krista. Hi, everyone. Welcome to Reddit's Fourth Quarter and Full Year 2025 Earnings Call. Joining me are Steve Huffman, Reddit's Co-Founder and CEO; Jen Wong, Reddit's COO; and Drew Vollero, Reddit's CFO.

I'd like to remind you that our remarks today will include forward-looking statements, and actual results may vary. Information concerning risks and other factors that could cause these results to vary is included in our SEC filings. These forward-looking statements represent our outlook only as of the date of this call, and we undertake no obligation to update any forward-looking statements.

During this call, we will discuss both GAAP and non-GAAP financials. Reconciliation of GAAP to

Bloom Energy Corporation (BE) Q4 2025 Earnings Call February 5, 2026 5:00 PM EST

Company Participants

Michael Tierney
K. Sridhar - Co-Founder, CEO & Chairman
Maciej Kurzymski - Chief Accounting Officer & Interim CFO

Conference Call Participants

David Arcaro - Morgan Stanley, Research Division
Christopher Dendrinos - RBC Capital Markets, Research Division
Manav Gupta - UBS Investment Bank, Research Division
Davis Sunderland - Robert W. Baird & Co. Incorporated, Research Division
Michael Blum - Wells Fargo Securities, LLC, Research Division
Colin Rusch - Oppenheimer & Co. Inc., Research Division
Mark W. Strouse - JPMorgan Chase & Co, Research Division
Sherif Elmaghrabi - BTIG, LLC, Research Division
Noel Parks - Tuohy Brothers Investment Research, Inc.

Presentation

Operator

Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bloom Energy Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions]

I would now like to turn the conference over to Michael Tierney, Vice President of Investor Relations. You may begin.

Michael Tierney

Thank you, and good afternoon, everybody. Thank you for joining us for Bloom Energy's Fourth Quarter and Full Year 2025 Earnings Call. To supplement this conference call, we furnished our fourth quarter and full year 2025 earnings press release with the SEC on Form 8-K and have posted along with supplemental financial information that we will reference throughout this call to our Investor Relations website.

During this conference call, both in our prepared remarks and in answers to your questions, we may make forward-looking statements that represent our expectations regarding future events and our future financial performance. These include statements about the company's business results, products, new markets, strategy, financial position, liquidity and full year outlook for 2026. These statements are predictions based upon our expectations, estimates and assumptions. However, as these statements deal with future events, they are subject to

CME Group delivered strong Q4 results with revenue up to $1.65B and expanding profit margins. Equity index, metals, and agricultural commodity contracts drove robust fee revenue growth; market data services revenue rose 14.5%. Despite operational excellence and new product launches, CME trades at lofty valuation multiples versus peers, warranting caution.

Bitcoin's drop below Strategy's roughly $76,000 average purchase price has pushed its holdings back into an unrealized loss.

Key takeawys:

Bitcoin fell below $63,000 as weak US job data and concerns over AI industry investments fueled investor risk aversion.

Options markets show a 6% chance of Bitcoin returning to $90,000 by March.

Bitcoin (BTC) slid below $63,000 on Thursday, hitting its lowest level since November 2024. The 30% drop since the failed attempt to break $90,500 on Jan. 28 has left traders skeptical of any immediate bullish momentum. The current bearish sentiment is fueled by weak US job market data and rising concerns over massive capital expenditure within the artificial intelligence sector.

Regardless of whether Bitcoin’s slump was triggered by macroeconomic shifts, options traders are now pricing in just 6% odds of BTC reclaiming $90,000 by March.

Deribit March BTC options pricing on Feb. 5. Source: Deribit / CointelegraphOn Deribit exchange, the right to buy Bitcoin at $90,000 on March 27 (a call option) traded at $522 on Thursday. This pricing suggests investors see little chance of a massive rally. According to the Black-Scholes model, these options reflect less than 6% odds of Bitcoin reaching $90,000 by late March. For context, the right to sell Bitcoin at $50,000 (a put option) for the same date traded at $1,380, implying a 20% probability of a deeper crash.

Quantum computing risks and forced liquidation fears drive Bitcoin sellingMarket participants have reduced crypto exposure due to emerging quantum computing risks and fears of forced liquidations by companies that built Bitcoin reserves through debt and equity. In mid-January, Christopher Wood, global head of equity strategy at Jefferies, removed a 10% Bitcoin allocation from his model portfolio, citing the risk of quantum computers reverse-engineering private keys.

Bitcoin holdings from public companies, USD. Source: bitcontreasuries.netStrategy (MSTR US), the largest publicly listed company with onchain BTC reserves, recently saw its enterprise value dip to $53.3 billion, while its cost basis sat at $54.2 billion. Japan’s Metaplanet (MPJPY US) faced a similar gap, valued at $2.95 billion against a $3.78 billion acquisition cost. Investors are worried that a prolonged bear market might force these companies to sell their positions to cover debt obligations.

External factors likely contributed to the rise in risk aversion, and even silver, the second-largest tradable asset by market capitalization, suffered a 36% weekly price drop after reaching a $121.70 all-time high on Jan. 29. 

Bitcoin/USD vs. Thomson Reuters, PayPal, Robinhood, Applovin and Silver/USD. Source: TradingView / CointelegraphBitcoin’s 27% weekly decline closely mirrors losses seen in several billion-dollar listed companies, including Thomson Reuters (TRI), PayPal (PYPL), Robinhood (HOOD) and Applovin (APP). 

US employers announced 108,435 layoffs in January, up 118% from the same period in 2025, according to outplacement firm Challenger, Gray & Christmas. The surge marked the highest number of January layoffs since 2009, when the economy was nearing the end of its deepest downturn in 80 years.

Market sentiment had already weakened after Google (GOOG US) reported on Wednesday that capital expenditure in 2026 is expected to reach $180 billion, up from $91.5 billion in 2025. Shares of tech giant Qualcomm (QCOM US) fell 8% after the company issued weaker growth guidance, citing that supplier capacity has been redirected toward high-bandwidth memory for data centers.

Traders expect investments in artificial intelligence to take longer to pay off due to rising competition and production bottlenecks, including energy constraints and shortages of memory chips. 

Bitcoin’s slide to $62,300 on Thursday reflects uncertainty around economic growth and US employment, making a rebound toward $90,000 in the near term increasingly unlikely.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

Bitcoin Solana XRP

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Tim Hakki

Web 3 Journalist

Tim Hakki

Part of the Team Since

Feb 2024

About Author

A journalist and copywriter with a decade's experience across music, video games, finance and tech.

Has Also Written

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Last updated: 

1 hour ago

When fed specially crafted prompts, DeepSeek’s AI model generates details of some lofty price projections for XRP, Solana, and Bitcoin by the end of the year.

According to DeepSeek’s analysis, an extended crypto bull market combined with clearer, more supportive regulation in the United States could propel leading digital assets to fresh record highs over the next eleven months.

Below, we outline DeepSeek’s hypotheses for the three top cryptocurrencies.

XRP ($XRP): DeepSeek AI Predicts a Move Toward $10 by 2027Ripple’s XRP ($XRP) is the biggest cryptocurrency token in the sector of institutional-grade cross-border payments. Currently trading at $1.35, DeepSeek estimates that a sustained bullish environment could push XRP as high as $10 by the end of 2026. That outcome would represent gains of around 640%, or close to 7.5x from current levels.

Source: DeepSeekXRP was among the top-performing large-cap cryptocurrencies last year. In July, it recorded its first new all-time high (ATH) in seven years, surging to $3.65 after Ripple secured a decisive legal victory against the U.S. Securities and Exchange Commission.

That ruling removed a significant regulatory hurdle for XRP and eased broader concerns about the SEC going after altcoins as unlicensed securities.

From a technical standpoint, XRP’s Relative Strength Index currently sits near 20, placing it in oversold territory. This suggests the selloff is nearing exhaustion, with buyers likely stepping in at current prices to take advantage of the relative discount.

Meanwhile, XRP’s January support and resistance levels are forming an emerging bullish flag pattern, a setup that often precedes breakouts.

Additionally, institutional inflows from recently approved XRP ETFs in the US, and expectations surrounding the CLARITY bill, a comprehensive regulatory framework for crypto, could serve as catalysts for a renewed breakout.

Solana (SOL): DeepSeek AI Projects SOL at $500 or HigherThe Solana ($SOL) ecosystem now supports $7 billion in total value locked (TVL) and carries a market capitalization above $50 billion, underpinned by consistent growth in utility, developer activity, and daily users.

Source: DeepSeekInterest in SOL has accelerated following the release of Solana-based ETFs from major asset managers such as Bitwise and Grayscale.

After a steep correction in late 2025, SOL spent recent months consolidating around a critical support zone and currently trades near $90. Right now, as with most cryptos, SOL is tracking Bitcoin’s price, so if Bitcoin reclaims the $100,000 level, a milestone that it could hit before midyear, then this will light the path for a quick SOL rebound.

Under DeepSeek’s most bullish scenario, Solana could climb to $500 by 2027. That would equate to nearly 500% upside from current prices and would push SOL well beyond its previous all-time high of $293, set last January.

Institutional adoption continues to strengthen Solana’s long-term narrative. The network is increasingly being used for real-world asset tokenization, with firms such as Franklin Templeton and BlackRock pointing to Solana’s expanding role within traditional financial infrastructure.

Bitcoin (BTC): DeepSeek AI Charts a Path to $250,000Bitcoin ($BTC), the original cryptocurrency and largest by market capitalization, reached a new all-time high of $126,080 on October 6.

Source: DeepSeekDespite the correction, DeepSeek indicates that Bitcoin’s broader year-over-year uptrend remains intact, with long-term price targets extending toward $250,000 by 2027.

Often referred to as digital gold, Bitcoin continues to attract institutional and retail investors seeking a potential hedge against inflation and macroeconomic volatility.

Bitcoin currently capitalizes $1.4 trillion of the $2.46 trillion total cryptocurrency market. Since hitting its ATH, BTC has fallen by around 44.5% and now trades near $70,400 following two sharp market downturns driven by global geopolitical uncertainty over potential US military action in Iran and Greenland.

Looking beyond near-term geopolitical risks, DeepSeek’s analysis highlights rising institutional participation and post-halving supply constraints as key forces that could drive Bitcoin to multiple new highs this year.

In addition, if U.S. policymakers move forward with proposals to establish a Strategic Bitcoin Reserve, Bitcoin’s long-term upside could exceed even DeepSeek’s already optimistic forecasts.

Maxi Doge (MAXI): The New Alpha in DogesvilleFinally, outside of DeepSeek’s data-driven projections, Maxi Doge ($MAXI) has become one of the most discussed meme coin presales of 2026, raising $4.6 million ahead of its public debut.

The project’s avatar is a high-energy parody (and distant cousin) of Dogecoin, blending gym-bro aesthetics with unapologetic degen humor. Loud, pumped, and intentionally outrageous, Maxi Doge leans fully into the irreverent fun that first made Dogecoin and Shiba Inu crypto sensations.

MAXI is issued as an ERC-20 token on Ethereum’s proof-of-stake network, giving it a significantly lower environmental footprint compared to Dogecoin’s proof-of-work model.

During the presale, buyers can stake MAXI tokens to earn yields of up to 68% APY, with rewards gradually decreasing as the staking pool grows. The token is currently priced at $0.0002802 in the latest presale stage, with automatic price increases applied at each funding milestone. Purchases are supported via MetaMask and Best Wallet.

Say goodbye to Dogecoin. Maxi Doge is the new alpha in Dogesville!

Stay updated through Maxi Doge’s official X and Telegram pages.

Visit the Official Website Here

Bitwise has become the first asset manager to make a formal move toward a Uniswap-focused exchange-traded fund.

In brief Major digital asset treasuries are massively down on their investments, according to data from Artemis. Leading firms Strategy and BitMine hold the biggest paper losses of $9.2 billion and $8.4 billion, respectively. Even firms stacking Solana (SOL), Hyperliquid (HYPE), and BNB are posting sizable unrealized losses. Prominent digital asset treasuries (DATs), including Bitcoin behemoth Strategy (MSTR) and leading Ethereum firm BitMine Immersion Technologies (BMNR), are now well down on their crypto investments, according to data gathered by blockchain analytics firm Artemis. 

The losses are growing among firms that are primarily focused on amassing cryptocurrency, with BMNR down around $8.4 billion on its Ethereum purchases as Strategy holds $9.2 billion in paper losses on its consistent Bitcoin buys.

The unrealized losses have quickly multiplied on account of the top crypto assets slide in the last week. BTC, which is down 13% in the last 24 hours, has fallen 24% in the last seven days to change hands around $63,708. 

Meanwhile, Ethereum has fared even worse, dropping almost 34% in the last seven days and falling to its lowest mark since last May, recently changing hands around $1,867. 

The Artemis data does not include crypto-centric firms that have a primary business focus outside of buying and holding assets—such as exchange Coinbase and mining firm Riot Platforms—or companies with a core business outside of crypto that have amassed a position in digital assets (like Tesla and GameStop).

Despite a major drop in prices for the asset, Strategy co-founder and Executive Chairman Michael Saylor remains undeterred, recently telling followers on X that there are only two rules related to Bitcoin. 

“1. Buy Bitcoin. 2. Don’t sell Bitcoin,” he posted earlier this week. 

While selling Bitcoin would invalidate those rules, the firm’s chairman changed his tune near the end of last year as it relates to the practicalities of his BTC business, saying that he needed to “dispel the notion” that the firm “couldn't or wouldn't” sell BTC to fund its dividends product. 

With the losses mounting, predictors on Myriad’s prediction market believe it’s more likely that Strategy may sell some of its BTC holdings sometime this year. In the last week, odds of the firm selling any of its 713,502 BTC have jumped to around 32%.

It’s not just the leading treasuries or those stacking BTC or ETH that are hurting, though. The Artemis dashboard accounts for more than $25 billion in losses, including around $1 billion in unrealized losses for Solana treasury firm Forward Industries and more than $100 million in paper losses for firms stacking Hyperliquid (HYPE) and BNB.

The DAT unwind has led to scrutiny from traditional financial analysts, with Joe Weisenthal of Bloomberg taking a shot at the premise on Thursday via an X post: "It's hard not to think that the explosion of DAT companies last year, where various crypto holders exchanged their tokens for inflated equity, was a big last gasp for this industry."

Crypto-natives have been critical too, with some prodding Lee and Saylor on social media about their firms. Last year, interim CEO of Solana business and treasury firm SOL Strategies, Michael Hubbard, told Decrypt he believed there was “no sustainable market for digital asset treasuries,” adding that staking ETFs would ultimately “eat their lunch.”

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Lately, veteran trader Peter Brandt has been flashing a bearish read on bitcoin, leaning on old-school chart work, familiar technical formations in recent price action, and the kind of market scar tissue that only decades of trading can provide.

Journalist

Posted: February 6, 2026

Cardano, Chainlink, and Stellar are set to score new institutional milestones.

From the 9th of February, the Chicago Mercantile Exchange (CME) will support Futures products for these altcoins, opening a new venue for big players to gain exposure.

As with past crypto offerings, there will be both large and micro-sized contracts.

For ADA, the bigger size contract will contain 100K ADA coins, while the smaller one will have 10K ADA.

Source: CME

Chainlink’s contracts will contain 5K Chainlink [LINK] and 250 LINK coins for the larger and micro offerings, respectively.

Finally, Stellar’s larger contract will have 250K Stellar [XLM], and the smaller version will have 12,500 XLM. 

The latest addition will expand CME’s crypto portfolio to seven assets, covering Bitcoin, Ethereum [ETH], Solana, and Ripple [XRP]. 

According to Giovanni Vicioso, CME Group global head of crypto products, the latest additions will offer investors more tools to gain exposure in the growing markets. He added, 

“Market participants will now have greater choice with enhanced flexibility and more capital efficiencies.”

For his part, Martin Franchi, CEO of NinjaTrader, billed the move as a ‘watershed moment for the futures industry’ and underscored the growing appetite for the new asset class. 

“Digital assets are reaching a global inflection point as they become increasingly mainstream and more deeply integrated into investors’ portfolios.”

Worth pointing out, however, these are structural developments and hardly viewed as bullish updates.

For example, when Solana’s CME Futures debuted on the 17th of March 2025, it did $12 million in notional volume. But the price remained sideways below $130 amid broader weak sentiment. 

Similarly, the XRP CME Futures launch on the 19th May 2025 saw $19 million in notional volume, but the altcoin’s price dipped afterward. 

As such, similar muted market reactions may play out for Cardano [ADA], LINK, or XLM, especially if the current risk-off environment extends to the launch date. 

What’s next for ADA and LINK? Meanwhile, whales were jumping on ADA as the price slipped lower to $0.2. Whale wallets holding 1 million to 10 million ADA, and those holding 100 million ADA, have been adding positions over the past few weeks. 

Source: Santiment

LINK also showed structural strength, with overall selling pressure, as indicated by Supply on Exchanges, remaining relatively low around 119 million LINK.

This was comparable to selling pressure in late 2025, signalling a measured dump. 

Source: Santiment

If the altcoin season momentum flips back to positive, the fundamentals could lift LINK and ADA.

That said, ADA was down 8.5% in the past 24 hours while LINK traded at $9 after shedding 8%. XLM also posted 8% loss as the crypto rout deepened. 

Final Thoughts  CME Futures’ expansion to ADA, LINK, and XLM underscored deepening institutional exposure to altcoins. However, the February 9 launch may be met with less market optimism amid a broader risk-off environment. 

The Ethereum Foundation has awarded a strategic grant to Certora to advance zkEVM security in collaboration with Powdr Labs. The initiative focuses on the verification of “Autoprecompiles,” optimized zero-knowledge (ZK) circuit components designed to drastically improve computational performance. Certora CEO Seth Hallem stated that the project is fundamental to ensuring the network’s most advanced scalability infrastructure has rigorous mathematical validation at its core.

Certora is formally verifying @powdr_labs autoprecompiles, supported by a grant from @ethereumfndn.

All specs + proofs will be open-sourced for the ZK ecosystem 🫡 https://t.co/TiDeLgI4SZ

— Certora (@Certora) February 5, 2026

The implementation of these components allows the current execution model to be replaced by a ZK-enabled alternative, which means higher speed, increased security, and a decrease in gas costs. By automatically inferring low-level components, the zkEVM can efficiently process complex cryptographic operations.

As part of the agreement, Certora will open-source its specifications and verification frameworks, allowing Rollup developers and ZK protocol researchers to utilize this infrastructure. The next step will be to monitor the integration of these tools into Ethereum’s various execution layers. The market will be watching how these automated verification techniques reduce manual errors and accelerate the mass adoption of Layer 2 solutions based on zero-knowledge technology.

Source:https://x.com/Certora/status/2019441186339962915

Disclaimer: Crypto Economy Flash News is prepared from official and public sources verified by our editorial team. Its purpose is to provide rapid information on relevant events in the crypto and blockchain ecosystem. This information does not constitute financial advice or investment recommendations. We recommend always verifying the official channels of each project before making related decisions.